DRUG APPROVALS
October 14, 2022
New Dual Incretin Agonist for Type 2 Diabetes
This first-in-class, once-weekly injectable agent has demonstrated significant positive outcomes in reducing A1C and weight in clinical trials.
October 14, 2022
Review of Selected NMEs 2022
October 14, 2022
New Drug Review 2022
October 14, 2022
Novel Drug Approvals in the United States
June 16, 2022
Dispelling Generic Drug Myths and Misconceptions
October 15, 2021
Azstarys in Ora-Blend Single Dose
October 15, 2021
Recent Trends in Approvals of Novel Drugs
October 15, 2021
Review of Selected NMEs 2021
October 15, 2021
New Drug Review 2021
October 16, 2020
New Drug Review 2020
October 16, 2019
Review of Selected NMEs 2019
October 16, 2019
New Drug Review 2019
Copyright © 2000 - 2022 Jobson Medical Information LLC unless otherwise noted. All rights reserved. Reproduction in whole or in part without permission is prohibited.